PS
IBRX icon

Planning Strategies’s ImmunityBio IBRX Stock Holding History

Planning Strategies’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$876 Buy
+100
New +$757 ﹤0.01% 766

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Planning Strategies's IBRX Position: Q2 2026 in Review

Planning Strategies opened a new position in ImmunityBio (IBRX) in Q2 2026: 100 shares worth $876. The stake represents ﹤0.01% of the portfolio and ranks #766 among its holdings.

377 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Planning Strategies held 100 shares of ImmunityBio worth $876 as of Q2 2026.
  • ImmunityBio was a new Planning Strategies position in Q2 2026.
  • ImmunityBio made up ﹤0.01% of Planning Strategies's portfolio in Q2 2026, its #766 holding.
  • 377 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Planning Strategies's 13F filing for Q2 2026, filed 27 Jul 2026.